Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Flippot

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Scientific Reports|January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic driversGabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance statusLucía Carril-Ajuria, Emeline Colomba, Carmen Romero-Ferreiro, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Nature Medicine|January 7, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinomaCarolina Alves Costa Silva, Marc Machaalani, Renee Maria Saliby, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Scientific Reports|January 22, 2020
Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic driversGabriel G Malouf, Ronan Flippot, Yiyu Dong, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance statusLucía Carril-Ajuria, Emeline Colomba, Carmen Romero-Ferreiro, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Nature Medicine|January 7, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinomaCarolina Alves Costa Silva, Marc Machaalani, Renee Maria Saliby, et al.
Cancer Immunology Research|June 6, 2023
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell CarcinomaRenee Maria Saliby, Talal El Zarif, Ziad Bakouny, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
European Urology Oncology|April 25, 2024
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP StudyRonan Flippot, Tugce Telli, Maud Velev, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
JAMA Oncology|October 21, 2021
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell CarcinomaLaure Hirsch, Nieves Martinez Chanza, Subrina Farah, et al.
Pageof 8